Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?-Reference-Cited by-同舟云学术

Is the Homologous Recombination Repair Mutation Defined by a 15-Gene Panel Associated with the Prognosis of Epithelial Ovarian Cancer?

Published:2024-07-05 Issue:5 Volume:28 Page:621-632
ISSN:1177-1062
Container-title:Molecular Diagnosis & Therapy
language:en
Short-container-title:Mol Diagn Ther

Author:

Liu Yi,Chen Xiaojun,Lu Huaiwu,Wu Xin,Liu Xuehan,Xu Fei,Ye Dongdong,Ding Bo,Lu Xiaoyan,Qiu Ling,Zhu Jing,Wang Yingying,Huang Xinya,Shen Zhen,Zhu Tao,Shen Yang,Zhou Ying^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40291-024-00726-w.pdf

Reference47 articles.

1. Ghose A, Bolina A, Mahajan I, et al. hereditary ovarian cancer: towards a cost-effective prevention strategy. Int J Environ Res Public Health. 2022. https://doi.org/10.3390/ijerph191912057.

2. Siegel RL, Miller KD, Wagle NS, et al. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. https://doi.org/10.3322/caac.21763.

3. Pavlidis N, Rassy E, Vermorken JB, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75: 102045. https://doi.org/10.1016/j.canep.2021.102045.

4. González-Martín A, Pothuri B, Vergote I, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381(25):2391–402. https://doi.org/10.1056/NEJMoa1910962.

5. Coleman RL, Fleming GF, Brady MF, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med. 2019;381(25):2403–15. https://doi.org/10.1056/NEJMoa1909707.